<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00741585</url>
  </required_header>
  <id_info>
    <org_study_id>HYGIA</org_study_id>
    <secondary_id>Hygia-2007-440</secondary_id>
    <nct_id>NCT00741585</nct_id>
  </id_info>
  <brief_title>Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment</brief_title>
  <acronym>HYGIA</acronym>
  <official_title>Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vigo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Servicio Gallego de Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vigo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HYGIA study was designed to investigate prospectively

        1. the prognostic value of ambulatory blood pressure (BP) monitoring among subjects
           primarily evaluated at primary care settings

        2. the impact of changes in ambulatory BP during follow-up in cardiovascular,
           cerebrovascular, metabolic, and renal risk in hypertensive patients

        3. the influence of circadian time of treatment in cardiovascular, cerebrovascular,
           metabolic, and renal risk in hypertensive patients

        4. the prevalence of an altered BP profile as a function of antihypertensive treatment,
           circadian time of treatment, age, and presence of diabetes, among other factors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ambulatory blood pressure (BP) measurements (ABPM) correlate more closely with target organ
      damage and cardiovascular events than clinical cuff measurements. ABPM reveals the
      significant circadian variation in BP, which in most individuals presents a morning increase,
      small post-prandial decline, and more extensive lowering during nocturnal rest. However,
      under certain pathophysiological conditions, the nocturnal BP decline may be reduced
      (non-dipper pattern) or even reversed (riser pattern). This is clinically relevant since the
      non-dipper and riser circadian BP patterns constitute a risk factor for left ventricular
      hypertrophy, albuminuria, cerebrovascular disease, congestive heart failure, vascular
      dementia, and myocardial infarction. Hence, there is growing interest in how to best tailor
      and individualize the treatment of hypertension according to the specific circadian BP
      pattern of each patient.

      The reduction of the normal 10-20% sleep-time BP decline that is characteristic of the
      non-dipper and riser patterns is indeed associated with elevated risk of target organ damage,
      particularly to the heart (left ventricular hypertrophy, congestive heart failure, and
      myocardial infarction), brain (stroke), and kidney (albuminuria and progression to end-stage
      renal failure). These results suggest that cardiovascular risk could be influenced not by BP
      elevation alone, but also by the magnitude of the circadian BP variability. However, the
      potential dimension of an altered BP profile is still under debate, as there is current
      discrepancy on the actual prevalence of a non-dipper BP profile among groups of interest,
      mainly the elderly, patients with diabetes and patients with resistant hypertension.

      Moreover, several independent prospective studies have suggested that nighttime BP may be a
      better predictor of cardiovascular risk than daytime BP. Common to all previous trials is
      that prognostic significance of ABPM has relied on a single baseline profile from each
      participant, without accounting for possible changes in the BP pattern, mainly associated to
      antihypertensive therapy and aging during follow-up. Moreover, the potential benefit, i.e.,
      reduction in cardiovascular risk, associated with the normalization of the circadian BP
      variability (e.g., conversion from non-dipper to dipper pattern) from appropriately
      envisioned treatment strategy is still a matter of debate.

      The HYGIA study was designed to investigate, first, the comparative prognostic value of
      several BP parameters (including, among many others, BP variability, the diurnal/nocturnal
      ratio, diurnal and nocturnal means, hyperbaric index, slope of morning rise, etc) in the
      prediction of vascular, metabolic, and renal morbidity and mortality; second, whether
      potential changes in the circadian BP pattern after treatment with hypertension medications
      may be associated to changes in the risk of cardiovascular events, stroke, diabetes, and/or
      chronic kidney disease; and third, in keeping with the second major objective above, to
      further assess the potential changes in efficacy, safety profile, and/or capability of
      hypertension medications, used either alone or in combination, to modulate the circadian BP
      pattern and to reduce vascular, metabolic, and renal risks as a function of the circadian
      time of administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2008</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular, metabolic, and renal risk assessment.</measure>
    <time_frame>Yearly evaluation for at least ten years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the influence of circadian time of treatment in BP control of hypertensive patients.</measure>
    <time_frame>Yearly evaluation for at least ten years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the prevalence of an altered (non-dipper) BP profile in patients with resistant hypertension as a function of the circadian time of treatment.</measure>
    <time_frame>Yearly evaluation for at least ten years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the influence of diabetes and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.</measure>
    <time_frame>Yearly evaluation for at least ten years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the influence of age and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.</measure>
    <time_frame>Yearly evaluation for at least ten years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate, for all groups of interest, the prevalence and vascular, metabolic, and renal risk profile of white-coat hypertension.</measure>
    <time_frame>Yearly evaluation for at least ten years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate, for all groups of interest, the prevalence and vascular, metabolic, and renal risk profile of masked hypertension.</measure>
    <time_frame>Yearly evaluation for at least ten years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate, for all previous objectives, potential differences between men and women.</measure>
    <time_frame>Yearly evaluation for at least ten years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the impact of changes in ambulatory BP in vascular, metabolic, and renal risk assessment.</measure>
    <time_frame>Yearly evaluation for at least ten years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18000</enrollment>
  <condition>Essential Hypertension</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Stroke</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with all prescribed hypertension medications on awakening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with at least one prescribed hypertension medication at bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Any antihypertensive medication alone or in combination</intervention_name>
    <description>All drugs on awakening</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Olmesartan</other_name>
    <other_name>Irbesartan</other_name>
    <other_name>Candesartan</other_name>
    <other_name>Telmisartan</other_name>
    <other_name>Valsartan</other_name>
    <other_name>Atenolol</other_name>
    <other_name>Carvedilol</other_name>
    <other_name>Nevibolol</other_name>
    <other_name>Doxazosine</other_name>
    <other_name>Lercanidipine</other_name>
    <other_name>Manidipine</other_name>
    <other_name>Amlodipine</other_name>
    <other_name>Ramipril</other_name>
    <other_name>Enalapril</other_name>
    <other_name>Lisinopril</other_name>
    <other_name>Quinapril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Any antihypertensive medication alone or in combination</intervention_name>
    <description>One or more drugs at bedtime</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Olmesartan</other_name>
    <other_name>Irbesartan</other_name>
    <other_name>Candesartan</other_name>
    <other_name>Telmisartan</other_name>
    <other_name>Valsartan</other_name>
    <other_name>Atenolol</other_name>
    <other_name>Carvedilol</other_name>
    <other_name>Nevibolol</other_name>
    <other_name>Doxazosine</other_name>
    <other_name>Lercanidipine</other_name>
    <other_name>Manidipine</other_name>
    <other_name>Amlodipine</other_name>
    <other_name>Ramipril</other_name>
    <other_name>Enalapril</other_name>
    <other_name>Lisinopril</other_name>
    <other_name>Quinapril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ambulatory blood pressure monitoring</intervention_name>
    <description>Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>ABPM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects ≥18 years of age.

          -  High-normal BP or essential hypertension.

          -  Any subject with recommendation for evaluation with ABPM according to the 2007
             European Guidelines.

          -  Informed consent to participate in the study prior to any study procedures.

        Exclusion Criteria:

          -  Known or suspected contraindications to any potential medication under investigation.

          -  Shift-workers.

          -  Inability to communicate and comply with all study requirements.

          -  Persons directly involved in the execution of this protocol.

          -  Intolerants to the use of the ABPM device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramon C Hermida, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Vigo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ramon C Hermida, PhD</last_name>
    <phone>34986812148</phone>
    <email>rhermida@uvigo.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana E Ayala, MD, PhD</last_name>
    <phone>34986812148</phone>
    <email>dianaelva@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CS Friol</name>
      <address>
        <city>Friol</city>
        <state>Lugo</state>
        <zip>27220</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Gomez, MD</last_name>
      <phone>34639512093</phone>
      <email>Esther.Gomez.Sal@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Esther Gomez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Baiona</name>
      <address>
        <city>Baiona</city>
        <state>Pontevedra</state>
        <zip>36300</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco J Iglesias, MD</last_name>
      <phone>34986357239</phone>
      <email>FranciscoJavier.Iglesias.Mato@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Francisco J Iglesias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Bueu</name>
      <address>
        <city>Bueu</city>
        <state>Pontevedra</state>
        <zip>36930</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel A Aboal, MD</last_name>
      <phone>34986323313</phone>
      <email>miguel.angel.aboal.beato@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Miguel A Aboal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS A Estrada</name>
      <address>
        <city>La Estrada</city>
        <state>Pontevedra</state>
        <zip>26680</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Meijide, MD</last_name>
      <phone>34986573459</phone>
      <email>Luis.Meijide.Calvo@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Luis Meijide, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariana Carbon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria C Garcia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco Romero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria P Brea</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS A Guarda</name>
      <address>
        <city>La Guardia</city>
        <state>Pontevedra</state>
        <zip>36780</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan J Crespo, MD</last_name>
      <phone>34986614450</phone>
      <email>JuanJose.Crespo.Sabaris@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Juan J Crespo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raquel Fernandez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen M Fernandez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amelia Ferreras, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Quintans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Javier Rodriguez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pilar Rua, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurelio Alvarez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asuncion Cadilla</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Outeiro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Soto-Davila</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Valmiñor</name>
      <address>
        <city>Nigran</city>
        <state>Pontevedra</state>
        <zip>36250</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Hernaiz, MD</last_name>
      <phone>34655391498</phone>
      <email>Susana.Hernaiz.Valero@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Susana Hernaiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Panxón</name>
      <address>
        <city>Nigrán</city>
        <state>Pontevedra</state>
        <zip>36340</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose L Salgado, MD</last_name>
      <phone>34986368615</phone>
      <email>joseluis.salgado.conde@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Jose L Salgado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esperanza Parrado</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfredo Pereira</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Tomiño</name>
      <address>
        <city>Tomiño</city>
        <state>Pontevedra</state>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evangelina Filloy, MD</last_name>
      <phone>34-986-623411</phone>
      <email>evangelina.filloy.miguez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Evangelina Filloy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adolfo T Perez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nieves Turienzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dolores Cardalda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose C Varela</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisca Vazquez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bioengineering &amp; Chronobilogy Labs., University of Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon C Hermida, PhD</last_name>
      <phone>34986812148</phone>
      <email>rhermida@uvigo.es</email>
    </contact>
    <contact_backup>
      <last_name>Diana E Ayala, MD, PhD</last_name>
      <phone>34986812148</phone>
      <email>dianaelva@uvigo.es</email>
    </contact_backup>
    <investigator>
      <last_name>Ramon C Hermida, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana E Ayala, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Artemio Mojon, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose R Fernandez, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ignacio Alonso, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria J Fontao</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rita Soler</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susana Serrano</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital do Meixoeiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Perez, MD</last_name>
      <phone>34627517077</phone>
      <email>roberto.perez.alvarez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Roberto Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Calle Cuba</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36202</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felisa Dominguez, MD</last_name>
      <phone>34986416226</phone>
      <email>fdominguez@meditex.es</email>
    </contact>
    <investigator>
      <last_name>Felisa Dominguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS A Doblada</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36205</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Rios, MD</last_name>
      <phone>34986275121</phone>
      <email>teresa.rios.rey@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Teresa Rios, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Coia</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36209</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peregrina Eiroa, MD</last_name>
      <phone>34986209282</phone>
      <email>pereeiroa@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Peregrina Eiroa, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jesus C Nieto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Sardoma</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36214</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Dominguez, MD, PhD</last_name>
      <phone>34986416324</phone>
      <email>Manuel.Dominguez.Sardina@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Manuel Dominguez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Teis</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36216</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro A Callejas, MD</last_name>
      <phone>34986374229</phone>
      <email>PedroAntonio.Callejas.Cabanillas@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Pedro A Callejas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Vilaboa</name>
      <address>
        <city>Vilaboa</city>
        <state>Pontevedra</state>
        <zip>36141</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia M Gomara, MD</last_name>
      <phone>34986679229</phone>
      <email>SoniaMaria.Gomara.Villabona@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Sonia M Gomara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julio J Alvarez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarita Estevez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria C Ferreira</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS San Roque</name>
      <address>
        <city>Vilagarcía De Arousa</city>
        <state>Pontevedra</state>
        <zip>36600</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Envira Sineiro, MD</last_name>
      <phone>34986507448</phone>
      <email>Elvira.Sineiro.Galinanes@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Elvira Sineiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarita Alvariño</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis M Fontenla</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarita Fraga, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Llovo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rita Martinez</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Santiago Santidrian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Fingoi</name>
      <address>
        <city>Lugo</city>
        <zip>27002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Castiñeira, MD</last_name>
      <phone>34982251035</phone>
      <email>Carmen.Castineira.Perez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Carmen Castiñeira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria C Aguado</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Costa</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Domingo D Garcia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernardino Pardo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrique J Vazquez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Ourense</name>
      <address>
        <city>Orense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfonso Otero, MD, PhD</last_name>
      <phone>34988385625</phone>
      <email>Alfonso.Santiago.Otero.Gonzalez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Alfonso Otero, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CS Lerez</name>
      <address>
        <city>Pontevedra</city>
        <zip>36156</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Moya, MD</last_name>
      <phone>34986871496</phone>
      <email>ana.moya.alvarez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Ana Moya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andres Ruiz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurelia Constenla</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria I Franco</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.hygia.es</url>
    <description>Official web site for the study</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2008</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vigo</investigator_affiliation>
    <investigator_full_name>Ramon C. Hermida</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Ambulatory blood pressure monitoring</keyword>
  <keyword>Chronotherapy</keyword>
  <keyword>Circadian</keyword>
  <keyword>Non-dipper</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Resistant hypertension</keyword>
  <keyword>Total mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Quinapril</mesh_term>
    <mesh_term>Lercanidipine</mesh_term>
    <mesh_term>Manidipine</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Doxazosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

